These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26439891)

  • 41. Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease.
    Wolf M; Thadhani R
    Semin Dial; 2005; 18(4):302-6. PubMed ID: 16076353
    [TBL] [Abstract][Full Text] [Related]  

  • 42. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey.
    Cozzolino M; Brancaccio D; Cannella G; Messa P; Gesualdo L; Marangella M; LoDeserto C; Pozzato M; Rombolà G; Costanzo AM; di Luzio Paparatti U; Mazzaferro S;
    Nephrol Dial Transplant; 2012 Sep; 27(9):3588-94. PubMed ID: 22523119
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation.
    Andress DL
    Kidney Int; 2006 Jan; 69(1):33-43. PubMed ID: 16374421
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.
    Fernström A; Giæver J; Granroth B; Hylander B; Jensen G; Christensson A; Wikström B; Weiss L; Wrege U; Jacobson SH
    Scand J Urol Nephrol; 2011 Apr; 45(3):196-205. PubMed ID: 21366390
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.
    Salam SN; Khwaja A; Wilkie ME
    Drugs; 2016 May; 76(8):841-52. PubMed ID: 27142279
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
    Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
    J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel, selective vitamin D analog suppresses parathyroid hormone in uremic animals and postmenopausal women.
    Zella JB; Plum LA; Plowchalk DR; Potochoiba M; Clagett-Dame M; DeLuca HF
    Am J Nephrol; 2014; 39(6):476-83. PubMed ID: 24854296
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.
    Ureña-Torres P; Bridges I; Christiano C; Cournoyer SH; Cooper K; Farouk M; Kopyt NP; Rodriguez M; Zehnder D; Covic A
    Nephrol Dial Transplant; 2013 May; 28(5):1241-54. PubMed ID: 23328710
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors?
    Anderson JL; Vanwoerkom RC; Horne BD; Bair TL; May HT; Lappé DL; Muhlestein JB
    Am Heart J; 2011 Aug; 162(2):331-339.e2. PubMed ID: 21835295
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.
    Noonan W; Koch K; Nakane M; Ma J; Dixon D; Bolin A; Reinhart G
    Nephrol Dial Transplant; 2008 Dec; 23(12):3824-30. PubMed ID: 18644798
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future.
    Brandenburg V; Ketteler M
    Nutrients; 2022 Jul; 14(15):. PubMed ID: 35893866
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vitamin D and Clinical Outcomes in Dialysis.
    Parikh C; Gutgarts V; Eisenberg E; Melamed ML
    Semin Dial; 2015; 28(6):604-9. PubMed ID: 26424141
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vitamin D in chronic kidney disease.
    Chau YY; Kumar J
    Indian J Pediatr; 2012 Aug; 79(8):1062-8. PubMed ID: 22544696
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The pathophysiology of secondary hyperparathyroidism].
    Tokumoto M
    Clin Calcium; 2016 Jun; 26(6):821-9. PubMed ID: 27230837
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vitamin D therapy in chronic kidney disease: back to the future?
    Damasiewicz MJ; Kerr PG; Polkinghorne KR
    Clin Nephrol; 2015 Aug; 84(2):65-74. PubMed ID: 26152127
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pathophysiology of secondary hyperparathyroidism.].
    Kawarazaki H
    Clin Calcium; 2017; 27(4):515-520. PubMed ID: 28336827
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency.
    Galassi A; Ciceri P; Porata G; Iatrino R; Boni Brivio G; Fasulo E; Magagnoli L; Stucchi A; Frittoli M; Cara A; Cozzolino M
    Expert Opin Drug Saf; 2021 Nov; 20(11):1333-1349. PubMed ID: 33993809
    [No Abstract]   [Full Text] [Related]  

  • 60. Vitamin D and osteoporosis in chronic kidney disease.
    Lips P; Goldsmith D; de Jongh R
    J Nephrol; 2017 Oct; 30(5):671-675. PubMed ID: 28940158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.